Trial intelligence / Profile preview

Effects of Mutaflor on exercise-induced gastrointestinal dysfunction

2016-000573-20Phase 3Active

Sponsor: Department of Sports Medicine, Institute for Sport Sciences, Justu-Liebig-University of GieÃŸen
Start: Apr 2016
Modality: Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Countries: 1

Overview

Phase 3 trial of escherichia coli nissle 1917 in Exercise-induced gastrointestinal syndrome (EIGS), sponsored by Department of Sports Medicine, Institute for Sport Sciences, Justu-Liebig-University of GieÃŸen. Primary endpoint: 3-hour post-exercise levels of LPS. Started Apr 2016; status: active.

Drugs

escherichia coli nissle 1917

Conditions

Exercise-induced gastrointestinal syndrome (EIGS)

Beyond the preview

Go deeper on 2016-000573-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-000573-20.